2937.11.00.00/Somatrogon (Long-Acting Growth Hormone)/Japan

Somatrogon (Long-Acting Growth Hormone) from Japan

Somatrogon is a long-acting structural analogue of somatotropin created by linking human growth hormone to a CTP (C-terminal peptide) sequence from hCG beta subunit. This modification extends its half-life for weekly dosing in growth hormone deficiency. Classified in HTS 2937.11.00.00 as a chain-modified polypeptide analogue used primarily as a hormone.

Duty Rate — Japan → United States

15%

Rate breakdown

9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate

9903.05.860%Universal product exemption (U.S. note 52(b))

9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)

Calculate with your customs value Verify classification with AI

Import Tips

• Submit sequence analysis confirming CTP modification for chain-modified polypeptide classification

• Maintain validated cold chain (2-8°C) with temperature monitoring records

• Avoid bulk packaging declarations that might suggest non-hormonal protein status